Strategic focus Target acute ischemic stroke and vascular dementia by highlighting BrainsGate’s SPG stimulation platform as a novel CNS therapy, positioning opportunities with hospitals and stroke networks that are pursuing neurovascular interventions.

Clinical and regulatory potential Leverage ongoing and potential clinical data around SPG stimulation to engage with key KOLs and trial sponsors, aiming to secure partnerships or co-development deals that accelerate regulatory pathways and market access.

Commercial readiness Emphasize a scalable medical device platform suitable for hospital adoption, with a clear value proposition around improved cerebral perfusion; pursue early access programs and pilot installations in major stroke centers.

Funding signals Capitalize on recent $14M funding and favorable valuation to approach strategic investors and larger device manufacturers for collaboration, licensing, or acquisition discussions that could expand sales channels.

Growth-ready segments Identify adjacent markets in CNS vascular care and chronic SPG stimulation for dementia where payer case studies and health economics data can demonstrate cost savings and outcome improvements to widen market reach.